Varamir
Desk
News
Calendar
Pricing
Saved
Search
tickers or companies
⌘K
Start free
· no card
Sign in
GLUE compared with SVRA: revenue, margins and what each company keeps, and the suppliers and customers both name
GLUE
Monte Rosa Therapeutics, Inc.
Change
Mkt cap
Revenue
Revenue
SVRA
Savara Inc
Change
Mkt cap
Revenue
Revenue
vs
Compare
GLUE
Monte Rosa Therapeutics, Inc.
vs
SVRA
Savara Inc
Price
Mkt cap
Revenue
Revenue
Change
Change
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Save comparison
Copy link
Revenue flow
Desk
News
Calendar
Saved
Search
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Price
Supply-chain overlap
Revenue flow
GLUE: latest quarter is a loss; flow not drawable. SVRA: latest quarter not drawable.
Method
›
Price
rebased to 0%
1D
1W
1M
3M
YTD
1Y
5Y
1D
1W
1M
3M
YTD
1Y
5Y
GLUE, solid
SVRA, dashed
GLUE
Monte Rosa Therapeutics, Inc.
Change
10.76
▼
−1.02%
· post 10.60
Mkt cap
$918.0M
Revenue
$9M
Q2 FY26
Revenue
$124M
FY25
SVRA
Savara Inc
Change
4.83
▼
−2.53%
· post 4.83
Closed
Oct 30 '26
Mkt cap
$990.3M
Revenue
—
Revenue
—
vs
Compare
Closed
Oct 30 '26
GLUE
Monte Rosa Therapeutics, Inc.
vs
SVRA
Savara Inc
10.76
▼
−1.02%
post 10.60
Price
4.83
▼
−2.53%
post 4.83
$918.0M
Mkt cap
$990.3M
Q2 FY26
$9M
Revenue
—
FY25
$124M
Revenue
—
Change
Change
GLUE
10.76
▼
−1.02%
vs
SVRA
4.83
▼
−2.53%
Closed
Oct 30 '26
Supply-chain overlap
direct ties · both sides
Sources
›
direct ties · both sides
Only GLUE
0
None
Shared
0
No disclosed counterparties: GLUE.
Only SVRA
7
—
FUJIFILM Diosynth Biotechnologies
unlisted
supplier
—
GEMA Biotech
unlisted
supplier
—
Parexel
unlisted
supplier
—
PARI Pharma GmbH
unlisted
supplier
3 more · SVRA chain
›
Role chip = supplier or customer
—
= no ticker (unlisted)
Source: SEC EDGAR